Supernus Pharmaceuticals, Inc. (SUPN) · Nov 2, 2026 · Delisting
Delisting — Merger completed; Nasdaq suspension and Form 25 requested
Supernus’ delisting filing confirms the Indivior merger has closed and the legacy SUPN shares are being removed from Nasdaq as scheduled.
Supernus is transitioning into the combined Indivior-Supernus CNS platform, not shutting down. The all-stock merger was announced on August 3, 2026, approved by both shareholder groups on October 15, and scheduled to close before the November 2 market open; the successor company was expected to trade under the SUPN ticker beginning November 3.
This filing confirms the administrative final step, rather than introducing new business information. Supernus says the merger was consummated on November 2 and that it asked Nasdaq to suspend trading and file Form 25 to remove the legacy Supernus common stock from listing.
The market-facing change is the disappearance of the old SUPN security, not a new change to the operating thesis. The filing also says Supernus intends to use Form 15 to deregister the shares and suspend its Exchange Act reporting obligations. 〔0〕 That was already the expected mechanics of the announced transaction, so the event is confirmation, not a surprise.
Bottom line: This is a routine closing-and-delisting notice that completes the previously disclosed merger. It matters operationally because the standalone Supernus public company ceases to exist, but it does not materially change the merger story investors already knew.
Form 15 deregistration and reporting suspension
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!